Global Noninvasive Cancer Diagnostics Technology Supply, Demand and Key Producers, 2023-2029
Page: 124
Published Date: 02 Sep 2023
Category: Medical Devices & Consumables
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Noninvasive Cancer Diagnostics Technology market size is expected to reach $ 5810.7 million by 2029, rising at a market growth of 7.0% CAGR during the forecast period (2023-2029).
The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.
Noninvasive Cancer Diagnostics Technology is a process for the detection of disease through minimal incisions into the body. Noninvasive cancer diagnostic technologies provide fast and convenient procedures for noninvasive early detection of cancer and provide a valuable aid to the clinician and increased comfort to the patient.Noninvasive Cancer Diagnosis Technologies are used to identify breast, lung, blood, and other cancers.
This report studies the global Noninvasive Cancer Diagnostics Technology demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Noninvasive Cancer Diagnostics Technology, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Noninvasive Cancer Diagnostics Technology that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Noninvasive Cancer Diagnostics Technology total market, 2018-2029, (USD Million)
Global Noninvasive Cancer Diagnostics Technology total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Noninvasive Cancer Diagnostics Technology total market, key domestic companies and share, (USD Million)
Global Noninvasive Cancer Diagnostics Technology revenue by player and market share 2018-2023, (USD Million)
Global Noninvasive Cancer Diagnostics Technology total market by Type, CAGR, 2018-2029, (USD Million)
Global Noninvasive Cancer Diagnostics Technology total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Noninvasive Cancer Diagnostics Technology market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Precision Therapeutics, Affymetrix Inc., Gen-Probe Incorporated, AVIVA Biosciences Corporation, A&G Pharmaceutical, BIOVIEW Inc., Quest Diagnostics Incorporated, Digene Corporation and Laboratory Corporation of America Holdings., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Noninvasive Cancer Diagnostics Technology market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Noninvasive Cancer Diagnostics Technology Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Noninvasive Cancer Diagnostics Technology Market, Segmentation by Type
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others
Global Noninvasive Cancer Diagnostics Technology Market, Segmentation by Application
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others
Companies Profiled:
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
GRAIL, Inc
Guardant Health, Inc
Genomic Health, Inc.
Illumina, Inc
NeoGenomics Laboratories, Inc.
Biocept, Inc
Key Questions Answered
1. How big is the global Noninvasive Cancer Diagnostics Technology market?
2. What is the demand of the global Noninvasive Cancer Diagnostics Technology market?
3. What is the year over year growth of the global Noninvasive Cancer Diagnostics Technology market?
4. What is the total value of the global Noninvasive Cancer Diagnostics Technology market?
5. Who are the major players in the global Noninvasive Cancer Diagnostics Technology market?
Table of Contents
1 Supply Summary
1.1 Noninvasive Cancer Diagnostics Technology Introduction
1.2 World Noninvasive Cancer Diagnostics Technology Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Noninvasive Cancer Diagnostics Technology Total Market by Region (by Headquarter Location)
1.3.1 World Noninvasive Cancer Diagnostics Technology Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.3 China Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.4 Europe Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.5 Japan Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.6 South Korea Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.7 ASEAN Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.3.8 India Noninvasive Cancer Diagnostics Technology Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Noninvasive Cancer Diagnostics Technology Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Noninvasive Cancer Diagnostics Technology Major Market Trends
2.1 World Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.2 World Noninvasive Cancer Diagnostics Technology Consumption Value by Region
2.2.1 World Noninvasive Cancer Diagnostics Technology Consumption Value by Region (2018-2023)
2.2.2 World Noninvasive Cancer Diagnostics Technology Consumption Value Forecast by Region (2024-2029)
2.3 United States Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.4 China Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.5 Europe Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.6 Japan Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.7 South Korea Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.8 ASEAN Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
2.9 India Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029)
3.1 World Noninvasive Cancer Diagnostics Technology Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Noninvasive Cancer Diagnostics Technology Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Noninvasive Cancer Diagnostics Technology in 2022
3.2.3 Global Concentration Ratios (CR8) for Noninvasive Cancer Diagnostics Technology in 2022
3.3 Noninvasive Cancer Diagnostics Technology Company Evaluation Quadrant
3.4 Noninvasive Cancer Diagnostics Technology Market: Overall Company Footprint Analysis
3.4.1 Noninvasive Cancer Diagnostics Technology Market: Region Footprint
3.4.2 Noninvasive Cancer Diagnostics Technology Market: Company Product Type Footprint
3.4.3 Noninvasive Cancer Diagnostics Technology Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Noninvasive Cancer Diagnostics Technology Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Noninvasive Cancer Diagnostics Technology Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Noninvasive Cancer Diagnostics Technology Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Noninvasive Cancer Diagnostics Technology Consumption Value Comparison
4.2.1 United States VS China: Noninvasive Cancer Diagnostics Technology Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Noninvasive Cancer Diagnostics Technology Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Noninvasive Cancer Diagnostics Technology Companies and Market Share, 2018-2023
4.3.1 United States Based Noninvasive Cancer Diagnostics Technology Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023)
4.4 China Based Companies Noninvasive Cancer Diagnostics Technology Revenue and Market Share, 2018-2023
4.4.1 China Based Noninvasive Cancer Diagnostics Technology Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023)
4.5 Rest of World Based Noninvasive Cancer Diagnostics Technology Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Noninvasive Cancer Diagnostics Technology Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023)
5.1 World Noninvasive Cancer Diagnostics Technology Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Immunoassays
5.2.2 Molecular Diagnostics
5.2.3 Clinical Chemistry
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Noninvasive Cancer Diagnostics Technology Market Size by Type (2018-2023)
5.3.2 World Noninvasive Cancer Diagnostics Technology Market Size by Type (2024-2029)
5.3.3 World Noninvasive Cancer Diagnostics Technology Market Size Market Share by Type (2018-2029)
6.1 World Noninvasive Cancer Diagnostics Technology Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Medical Device Manufacturing Company
6.2.2 Oncology Laboratories
6.2.3 Government and Private Research Institutions
6.2.4 Academic Institutions and Pharmaceutical Companies
6.2.5 Academic Institutions and Pharmaceutical Companies
6.3 Market Segment by Application
6.3.1 World Noninvasive Cancer Diagnostics Technology Market Size by Application (2018-2023)
6.3.2 World Noninvasive Cancer Diagnostics Technology Market Size by Application (2024-2029)
6.3.3 World Noninvasive Cancer Diagnostics Technology Market Size by Application (2018-2029)
7.1 Precision Therapeutics
7.1.1 Precision Therapeutics Details
7.1.2 Precision Therapeutics Major Business
7.1.3 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Services
7.1.4 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Precision Therapeutics Recent Developments/Updates
7.1.6 Precision Therapeutics Competitive Strengths & Weaknesses
7.2 Affymetrix Inc.
7.2.1 Affymetrix Inc. Details
7.2.2 Affymetrix Inc. Major Business
7.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Services
7.2.4 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Affymetrix Inc. Recent Developments/Updates
7.2.6 Affymetrix Inc. Competitive Strengths & Weaknesses
7.3 Gen-Probe Incorporated
7.3.1 Gen-Probe Incorporated Details
7.3.2 Gen-Probe Incorporated Major Business
7.3.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Services
7.3.4 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Gen-Probe Incorporated Recent Developments/Updates
7.3.6 Gen-Probe Incorporated Competitive Strengths & Weaknesses
7.4 AVIVA Biosciences Corporation
7.4.1 AVIVA Biosciences Corporation Details
7.4.2 AVIVA Biosciences Corporation Major Business
7.4.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Services
7.4.4 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 AVIVA Biosciences Corporation Recent Developments/Updates
7.4.6 AVIVA Biosciences Corporation Competitive Strengths & Weaknesses
7.5 A&G Pharmaceutical
7.5.1 A&G Pharmaceutical Details
7.5.2 A&G Pharmaceutical Major Business
7.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Services
7.5.4 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 A&G Pharmaceutical Recent Developments/Updates
7.5.6 A&G Pharmaceutical Competitive Strengths & Weaknesses
7.6 BIOVIEW Inc.
7.6.1 BIOVIEW Inc. Details
7.6.2 BIOVIEW Inc. Major Business
7.6.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Services
7.6.4 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 BIOVIEW Inc. Recent Developments/Updates
7.6.6 BIOVIEW Inc. Competitive Strengths & Weaknesses
7.7 Quest Diagnostics Incorporated
7.7.1 Quest Diagnostics Incorporated Details
7.7.2 Quest Diagnostics Incorporated Major Business
7.7.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Services
7.7.4 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Quest Diagnostics Incorporated Recent Developments/Updates
7.7.6 Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
7.8 Digene Corporation
7.8.1 Digene Corporation Details
7.8.2 Digene Corporation Major Business
7.8.3 Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Services
7.8.4 Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Digene Corporation Recent Developments/Updates
7.8.6 Digene Corporation Competitive Strengths & Weaknesses
7.9 Laboratory Corporation of America Holdings.
7.9.1 Laboratory Corporation of America Holdings. Details
7.9.2 Laboratory Corporation of America Holdings. Major Business
7.9.3 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Services
7.9.4 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Laboratory Corporation of America Holdings. Recent Developments/Updates
7.9.6 Laboratory Corporation of America Holdings. Competitive Strengths & Weaknesses
7.10 GRAIL, Inc
7.10.1 GRAIL, Inc Details
7.10.2 GRAIL, Inc Major Business
7.10.3 GRAIL, Inc Noninvasive Cancer Diagnostics Technology Product and Services
7.10.4 GRAIL, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 GRAIL, Inc Recent Developments/Updates
7.10.6 GRAIL, Inc Competitive Strengths & Weaknesses
7.11 Guardant Health, Inc
7.11.1 Guardant Health, Inc Details
7.11.2 Guardant Health, Inc Major Business
7.11.3 Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Product and Services
7.11.4 Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Guardant Health, Inc Recent Developments/Updates
7.11.6 Guardant Health, Inc Competitive Strengths & Weaknesses
7.12 Genomic Health, Inc.
7.12.1 Genomic Health, Inc. Details
7.12.2 Genomic Health, Inc. Major Business
7.12.3 Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Product and Services
7.12.4 Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Genomic Health, Inc. Recent Developments/Updates
7.12.6 Genomic Health, Inc. Competitive Strengths & Weaknesses
7.13 Illumina, Inc
7.13.1 Illumina, Inc Details
7.13.2 Illumina, Inc Major Business
7.13.3 Illumina, Inc Noninvasive Cancer Diagnostics Technology Product and Services
7.13.4 Illumina, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Illumina, Inc Recent Developments/Updates
7.13.6 Illumina, Inc Competitive Strengths & Weaknesses
7.14 NeoGenomics Laboratories, Inc.
7.14.1 NeoGenomics Laboratories, Inc. Details
7.14.2 NeoGenomics Laboratories, Inc. Major Business
7.14.3 NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Product and Services
7.14.4 NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 NeoGenomics Laboratories, Inc. Recent Developments/Updates
7.14.6 NeoGenomics Laboratories, Inc. Competitive Strengths & Weaknesses
7.15 Biocept, Inc
7.15.1 Biocept, Inc Details
7.15.2 Biocept, Inc Major Business
7.15.3 Biocept, Inc Noninvasive Cancer Diagnostics Technology Product and Services
7.15.4 Biocept, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Biocept, Inc Recent Developments/Updates
7.15.6 Biocept, Inc Competitive Strengths & Weaknesses
8.1 Noninvasive Cancer Diagnostics Technology Industry Chain
8.2 Noninvasive Cancer Diagnostics Technology Upstream Analysis
8.3 Noninvasive Cancer Diagnostics Technology Midstream Analysis
8.4 Noninvasive Cancer Diagnostics Technology Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Noninvasive Cancer Diagnostics Technology Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Noninvasive Cancer Diagnostics Technology Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Noninvasive Cancer Diagnostics Technology Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Noninvasive Cancer Diagnostics Technology Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Noninvasive Cancer Diagnostics Technology Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Noninvasive Cancer Diagnostics Technology Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Noninvasive Cancer Diagnostics Technology Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Noninvasive Cancer Diagnostics Technology Players in 2022
Table 12. World Noninvasive Cancer Diagnostics Technology Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Noninvasive Cancer Diagnostics Technology Company Evaluation Quadrant
Table 14. Head Office of Key Noninvasive Cancer Diagnostics Technology Player
Table 15. Noninvasive Cancer Diagnostics Technology Market: Company Product Type Footprint
Table 16. Noninvasive Cancer Diagnostics Technology Market: Company Product Application Footprint
Table 17. Noninvasive Cancer Diagnostics Technology Mergers & Acquisitions Activity
Table 18. United States VS China Noninvasive Cancer Diagnostics Technology Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Noninvasive Cancer Diagnostics Technology Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Noninvasive Cancer Diagnostics Technology Companies, Headquarters (States, Country)
Table 21. United States Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Noninvasive Cancer Diagnostics Technology Revenue Market Share (2018-2023)
Table 23. China Based Noninvasive Cancer Diagnostics Technology Companies, Headquarters (Province, Country)
Table 24. China Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Noninvasive Cancer Diagnostics Technology Revenue Market Share (2018-2023)
Table 26. Rest of World Based Noninvasive Cancer Diagnostics Technology Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Noninvasive Cancer Diagnostics Technology Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Noninvasive Cancer Diagnostics Technology Revenue Market Share (2018-2023)
Table 29. World Noninvasive Cancer Diagnostics Technology Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Noninvasive Cancer Diagnostics Technology Market Size by Type (2018-2023) & (USD Million)
Table 31. World Noninvasive Cancer Diagnostics Technology Market Size by Type (2024-2029) & (USD Million)
Table 32. World Noninvasive Cancer Diagnostics Technology Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Noninvasive Cancer Diagnostics Technology Market Size by Application (2018-2023) & (USD Million)
Table 34. World Noninvasive Cancer Diagnostics Technology Market Size by Application (2024-2029) & (USD Million)
Table 35. Precision Therapeutics Basic Information, Area Served and Competitors
Table 36. Precision Therapeutics Major Business
Table 37. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product and Services
Table 38. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Precision Therapeutics Recent Developments/Updates
Table 40. Precision Therapeutics Competitive Strengths & Weaknesses
Table 41. Affymetrix Inc. Basic Information, Area Served and Competitors
Table 42. Affymetrix Inc. Major Business
Table 43. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product and Services
Table 44. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Affymetrix Inc. Recent Developments/Updates
Table 46. Affymetrix Inc. Competitive Strengths & Weaknesses
Table 47. Gen-Probe Incorporated Basic Information, Area Served and Competitors
Table 48. Gen-Probe Incorporated Major Business
Table 49. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product and Services
Table 50. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Gen-Probe Incorporated Recent Developments/Updates
Table 52. Gen-Probe Incorporated Competitive Strengths & Weaknesses
Table 53. AVIVA Biosciences Corporation Basic Information, Area Served and Competitors
Table 54. AVIVA Biosciences Corporation Major Business
Table 55. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product and Services
Table 56. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. AVIVA Biosciences Corporation Recent Developments/Updates
Table 58. AVIVA Biosciences Corporation Competitive Strengths & Weaknesses
Table 59. A&G Pharmaceutical Basic Information, Area Served and Competitors
Table 60. A&G Pharmaceutical Major Business
Table 61. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product and Services
Table 62. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. A&G Pharmaceutical Recent Developments/Updates
Table 64. A&G Pharmaceutical Competitive Strengths & Weaknesses
Table 65. BIOVIEW Inc. Basic Information, Area Served and Competitors
Table 66. BIOVIEW Inc. Major Business
Table 67. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product and Services
Table 68. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. BIOVIEW Inc. Recent Developments/Updates
Table 70. BIOVIEW Inc. Competitive Strengths & Weaknesses
Table 71. Quest Diagnostics Incorporated Basic Information, Area Served and Competitors
Table 72. Quest Diagnostics Incorporated Major Business
Table 73. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product and Services
Table 74. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Quest Diagnostics Incorporated Recent Developments/Updates
Table 76. Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
Table 77. Digene Corporation Basic Information, Area Served and Competitors
Table 78. Digene Corporation Major Business
Table 79. Digene Corporation Noninvasive Cancer Diagnostics Technology Product and Services
Table 80. Digene Corporation Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Digene Corporation Recent Developments/Updates
Table 82. Digene Corporation Competitive Strengths & Weaknesses
Table 83. Laboratory Corporation of America Holdings. Basic Information, Area Served and Competitors
Table 84. Laboratory Corporation of America Holdings. Major Business
Table 85. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product and Services
Table 86. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Laboratory Corporation of America Holdings. Recent Developments/Updates
Table 88. Laboratory Corporation of America Holdings. Competitive Strengths & Weaknesses
Table 89. GRAIL, Inc Basic Information, Area Served and Competitors
Table 90. GRAIL, Inc Major Business
Table 91. GRAIL, Inc Noninvasive Cancer Diagnostics Technology Product and Services
Table 92. GRAIL, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. GRAIL, Inc Recent Developments/Updates
Table 94. GRAIL, Inc Competitive Strengths & Weaknesses
Table 95. Guardant Health, Inc Basic Information, Area Served and Competitors
Table 96. Guardant Health, Inc Major Business
Table 97. Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Product and Services
Table 98. Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Guardant Health, Inc Recent Developments/Updates
Table 100. Guardant Health, Inc Competitive Strengths & Weaknesses
Table 101. Genomic Health, Inc. Basic Information, Area Served and Competitors
Table 102. Genomic Health, Inc. Major Business
Table 103. Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Product and Services
Table 104. Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Genomic Health, Inc. Recent Developments/Updates
Table 106. Genomic Health, Inc. Competitive Strengths & Weaknesses
Table 107. Illumina, Inc Basic Information, Area Served and Competitors
Table 108. Illumina, Inc Major Business
Table 109. Illumina, Inc Noninvasive Cancer Diagnostics Technology Product and Services
Table 110. Illumina, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Illumina, Inc Recent Developments/Updates
Table 112. Illumina, Inc Competitive Strengths & Weaknesses
Table 113. NeoGenomics Laboratories, Inc. Basic Information, Area Served and Competitors
Table 114. NeoGenomics Laboratories, Inc. Major Business
Table 115. NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Product and Services
Table 116. NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. NeoGenomics Laboratories, Inc. Recent Developments/Updates
Table 118. Biocept, Inc Basic Information, Area Served and Competitors
Table 119. Biocept, Inc Major Business
Table 120. Biocept, Inc Noninvasive Cancer Diagnostics Technology Product and Services
Table 121. Biocept, Inc Noninvasive Cancer Diagnostics Technology Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Noninvasive Cancer Diagnostics Technology Upstream (Raw Materials)
Table 123. Noninvasive Cancer Diagnostics Technology Typical Customers
List of Figure
Figure 1. Noninvasive Cancer Diagnostics Technology Picture
Figure 2. World Noninvasive Cancer Diagnostics Technology Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Noninvasive Cancer Diagnostics Technology Total Market Size (2018-2029) & (USD Million)
Figure 4. World Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Noninvasive Cancer Diagnostics Technology Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Noninvasive Cancer Diagnostics Technology Revenue (2018-2029) & (USD Million)
Figure 13. Noninvasive Cancer Diagnostics Technology Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 16. World Noninvasive Cancer Diagnostics Technology Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 18. China Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 23. India Noninvasive Cancer Diagnostics Technology Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Noninvasive Cancer Diagnostics Technology by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Noninvasive Cancer Diagnostics Technology Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Noninvasive Cancer Diagnostics Technology Markets in 2022
Figure 27. United States VS China: Noninvasive Cancer Diagnostics Technology Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Noninvasive Cancer Diagnostics Technology Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Noninvasive Cancer Diagnostics Technology Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Noninvasive Cancer Diagnostics Technology Market Size Market Share by Type in 2022
Figure 31. Immunoassays
Figure 32. Molecular Diagnostics
Figure 33. Clinical Chemistry
Figure 34. Others
Figure 35. World Noninvasive Cancer Diagnostics Technology Market Size Market Share by Type (2018-2029)
Figure 36. World Noninvasive Cancer Diagnostics Technology Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Noninvasive Cancer Diagnostics Technology Market Size Market Share by Application in 2022
Figure 38. Medical Device Manufacturing Company
Figure 39. Oncology Laboratories
Figure 40. Government and Private Research Institutions
Figure 41. Academic Institutions and Pharmaceutical Companies
Figure 42. Others
Figure 43. Noninvasive Cancer Diagnostics Technology Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Precision Therapeutics Affymetrix Inc. Gen-Probe Incorporated AVIVA Biosciences Corporation A&G Pharmaceutical BIOVIEW Inc. Quest Diagnostics Incorporated Digene Corporation Laboratory Corporation of America Holdings. GRAIL, Inc Guardant Health, Inc Genomic Health, Inc. Illumina, Inc NeoGenomics Laboratories, Inc. Biocept, Inc
Related Reports
17 May 2022
Medical Devices & Consumables
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
